Prospective Investigation of Serum Metabolites, Coffee Drinking, Liver Cancer Incidence, and Liver Disease Mortality
- 5 June 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 112 (3) , 286-294
Abstract
Background: Coffee has been consistently associated with lower risk of liver cancer and chronic liver disease, suggesting that coffee affects mechanisms underlying disease development. Methods: We measured serum metabolites using untargeted metabolomics in 1:1 matched nested case-control studies of liver cancer (n = 221 cases) and fatal liver disease (n = 242 cases) in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention cohort (n = 29 133). Associations between baseline coffee drinking and metabolites were identified using linear regression; conditional logistic regression models were used to identify associations with subsequent outcomes. Results: Overall, 21 metabolites were associated with coffee drinking and also each subsequent endpoint; nine metabolites and trigonelline, a known coffee biomarker, were identified. Tyrosine and two bile acids, glycochenodeoxycholic acid (GCDCA) and glycocholic acid (GCA), were inversely associated with coffee but positively associated with both outcomes; odds ratios (ORs) comparing the 90th to 10th percentile (modeled on a continuous basis) ranged from 3.93 (95% confidence interval [CI] = 2.00 to 7.74) for tyrosine to 4.95 (95% CI = 2.64 to 9.29) for GCA and from 4.00 (95% CI = 2.42 to 6.62) for GCA to 6.77 (95% CI = 3.62 to 12.65) for GCDCA for liver cancer and fatal liver disease, respectively. The remaining six metabolites and trigonelline were positively associated with coffee drinking but inversely associated with both outcomes; odds ratio ranged from 0.16 to 0.37. Associations persisted following diet adjustment and for outcomes occurring greater than 10 years after blood collection. Conclusions: A broad range of compounds were associated with coffee drinking, incident liver cancer, and liver disease death over 27 years of follow-up. These associations provide novel insight into chronic liver disease and liver cancer etiology and support a possible hepatoprotective effect of coffee.Keywords
Funding Information
- Intramural Research Program
- National Cancer Institute
- NCI
- National Institutes of Health (HHSN261201500005C)
- NCI
This publication has 51 references indexed in Scilit:
- Estimating the Receiver Operating Characteristic Curve in Studies That Match Controls to Cases on CovariatesAcademic Radiology, 2013
- Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohortAnnals of Oncology, 2013
- Consumption of coffee associated with reduced risk of liver cancer: a meta-analysisBMC Gastroenterology, 2013
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular CarcinomaMolecular & Cellular Proteomics, 2011
- Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus InfectionGastroenterology, 2011
- Carcinogenicity of deoxycholate, a secondary bile acidArchives of Toxicology, 2011
- Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C # ∥ ‡Hepatology, 2009
- Metabolic syndrome and hepatocellular carcinomaCancer, 2009
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005Journal of Clinical Oncology, 2009